2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
2seventy bio reported its second-quarter financial results and operational progress. Key highlights include:
1. Abecma generated $54 million in U.S. commercial revenue, reflecting significant demand growth.
2. Successfully completed the sale of its Hemophilia A and gene-editing technology to Novo Nordisk for up to $40 million.
Financial Metrics:
- Net income: $24.9 million, compared to a net loss of $42.1 million in Q2 2023.
- Total revenues: $9.0 million, down from $36.0 million in Q2 2023.
- Cash reserves: $202 million, with a cash runway extending beyond 2027.
The company reduced operating expenses by 43% quarter-on-quarter due to the sale of its oncology R&D business to Regeneron.
2seventy bio aims for quarterly profitability by late 2025 and anticipates further revenue growth for Abecma in the third quarter of 2024.
2seventy bio ha riportato i risultati finanziari del secondo trimestre e i progressi operativi. I punti salienti includono:
1. Abecma ha generato 54 milioni di dollari in entrate commerciali negli Stati Uniti, riflettendo una crescita significativa della domanda.
2. Completata con successo la vendita della sua tecnologia per l'emofilia A e l'editing genetico a Novo Nordisk per un massimo di 40 milioni di dollari.
Metriche Finanziarie:
- Utile netto: 24,9 milioni di dollari, rispetto a una perdita netta di 42,1 milioni di dollari nel Q2 2023.
- Ricavi totali: 9,0 milioni di dollari, in calo rispetto ai 36,0 milioni di dollari del Q2 2023.
- Riserve di cassa: 202 milioni di dollari, con una disponibilità di cassa che si estende oltre il 2027.
L'azienda ha ridotto le spese operative del 43% rispetto al trimestre precedente grazie alla vendita della sua divisione di R&S oncologiche a Regeneron.
2seventy bio punta a una redditività trimestrale entro la fine del 2025 e prevede una ulteriore crescita dei ricavi per Abecma nel terzo trimestre del 2024.
2seventy bio reportó sus resultados financieros del segundo trimestre y el progreso operativo. Los aspectos más destacados incluyen:
1. Abecma generó 54 millones de dólares en ingresos comerciales en EE. UU., reflejando un crecimiento significativo en la demanda.
2. Se completó con éxito la venta de su tecnología para la hemofilia A y la edición genética a Novo Nordisk por hasta 40 millones de dólares.
Métricas Financieras:
- Ingresos netos: 24,9 millones de dólares, en comparación con una pérdida neta de 42,1 millones de dólares en el Q2 2023.
- Ingresos totales: 9,0 millones de dólares, por debajo de los 36,0 millones de dólares en el Q2 2023.
- Reservas de efectivo: 202 millones de dólares, con una disponibilidad de efectivo que se extiende más allá de 2027.
La empresa redujo los gastos operativos en un 43% trimestre a trimestre debido a la venta de su negocio de I+D en oncología a Regeneron.
2seventy bio tiene como objetivo una rentabilidad trimestral para finales de 2025 y anticipa un crecimiento adicional en los ingresos de Abecma en el tercer trimestre de 2024.
2seventy bio는 2분기 재무 결과와 운영 진행 상황을 보고했습니다. 주요 하이라이트는 다음과 같습니다:
1. Abecma는 미국에서 5,400만 달러의 상업 수익을 기록하여 수요가 크게 증가했습니다.
2. Novo Nordisk에 혈우병 A 및 유전자 편집 기술을 최대 4천만 달러에 성공적으로 판매했습니다.
재무 지표:
- 순이익: 2,490만 달러로, 2023년 2분기에는 4,210만 달러의 순손실이었습니다.
- 총 수익: 900만 달러로, 2023년 2분기 3,600만 달러에서 감소했습니다.
- 현금 보유: 2억 2백만 달러로, 현금 런웨이는 2027년 이후까지 연장됩니다.
회사는 Regeneron에 온콜로지 연구개발 사업 부문을 판매함으로써 분기 대비 운영 비용을 43% 줄였습니다.
2seventy bio는 2025년 말까지 분기 수익성을 목표로 하고 있으며, 2024년 3분기 Abecma의 추가 수익 성장을 예상합니다.
2seventy bio a publié ses résultats financiers et ses avancées opérationnelles pour le deuxième trimestre. Les points clés incluent :
1. Abecma a généré 54 millions de dollars de revenus commerciaux aux États-Unis, reflétant une croissance significative de la demande.
2. Vente réussie de sa technologie pour l'hémophilie A et l'édition génomique à Novo Nordisk pour un montant pouvant atteindre 40 millions de dollars.
Métriques Financières :
- Revenu net : 24,9 millions de dollars, contre une perte nette de 42,1 millions de dollars au Q2 2023.
- Revenus totaux : 9,0 millions de dollars, en baisse par rapport à 36,0 millions de dollars au Q2 2023.
- Réserves de liquidités : 202 millions de dollars, avec une trésorerie s'étendant au-delà de 2027.
L'entreprise a réduit ses dépenses opérationnelles de 43 % d'un trimestre à l'autre grâce à la vente de son activité de recherche et développement en oncologie à Regeneron.
2seventy bio vise à atteindre la rentabilité trimestrielle d'ici fin 2025 et anticipe une nouvelle croissance des revenus pour Abecma au troisième trimestre de 2024.
2seventy bio hat seine finanziellen Ergebnisse und betrieblichen Fortschritte für das zweite Quartal bekannt gegeben. Die wichtigsten Highlights umfassen:
1. Abecma erzielte 54 Millionen Dollar an kommerziellen Einnahmen in den USA, was auf ein erhebliches Nachfragewachstum hinweist.
2. Erfolgreicher Abschluss des Verkaufs seiner Technologie zur Behandlung von Hämophilie A und zur Genbearbeitung an Novo Nordisk für bis zu 40 Millionen Dollar.
Finanzkennzahlen:
- Nettoeinkommen: 24,9 Millionen Dollar, im Vergleich zu einem Nettoverlust von 42,1 Millionen Dollar im Q2 2023.
- Gesamtumsatz: 9,0 Millionen Dollar, im Vergleich zu 36,0 Millionen Dollar im Q2 2023.
- Bargeldreserven: 202 Millionen Dollar, mit einer finanziellen Laufzeit, die über 2027 hinausgeht.
Das Unternehmen hat die Betriebsausgaben im Quartalsvergleich um 43 % gesenkt, da es seine Onkologie-Forschungs- und Entwicklungsabteilung an Regeneron verkauft hat.
2seventy bio strebt bis Ende 2025 eine vierteljährliche Rentabilität an und erwartet für das dritte Quartal 2024 ein weiteres Umsatzwachstum für Abecma.
- Abecma generated $54 million in U.S. commercial revenue.
- Completion of Hemophilia A and gene-editing technology sale to Novo Nordisk for $40 million.
- Net income of $24.9 million, a significant turnaround from a net loss of $42.1 million in Q2 2023.
- 43% reduction in operating expenses.
- Cash reserves of $202 million with a runway beyond 2027.
- Total Q2 revenues dropped to $9.0 million from $36.0 million in Q2 2023.
- Net loss of $27.8 million for the first six months of 2024, compared to $89.1 million in the same period in 2023.
Insights
2seventy bio's Q2 results show a significant transformation in their business model and financial position. The company reported
- Sale of oncology R&D business to Regeneron, resulting in a
43% quarter-on-quarter reduction in operating expenses - Sale of Hemophilia A program and gene editing technology to Novo Nordisk for up to
$40 million - Streamlined cost structure, with net cash spend range lowered to
$40-60 million for 2024
These moves have strengthened their balance sheet, with
The Abecma market dynamics present a mixed picture. While Q2 revenue was modest at
- Execution of third-line launch in H2 2024
- Competitive differentiation based on Abecma's safety and efficacy profile
- Impact of KarMMa-3 and real-world data on market perception
The collaboration with Bristol Myers Squibb, sharing profits and losses equally, adds stability but also complexity to revenue forecasting. The recent regulatory approval for earlier line treatment could expand Abecma's market potential, potentially driving future growth. However, investors should monitor the competitive landscape closely, as the CAR-T therapy market for multiple myeloma is becoming increasingly crowded.
The clinical implications of 2seventy bio's Q2 results are noteworthy. Abecma's approval for earlier line treatment in multiple myeloma is a significant advancement. This expansion could potentially benefit more patients and improve outcomes. Key clinical considerations include:
- Safety profile: Monitoring of cytokine release syndrome (CRS) and neurologic toxicities remains crucial
- Efficacy data: Real-world evidence will be vital to support the KarMMa-3 trial results
- Patient selection: Identifying suitable candidates for CAR-T therapy in earlier treatment lines
The company's focus on Abecma allows for concentrated efforts in optimizing its use and potentially expanding indications. However, the reported cases of secondary malignancies, particularly myeloid neoplasms, warrant careful long-term follow-up and risk assessment. This aspect could influence treatment decisions and regulatory considerations moving forward.
Following regulatory approval in the earlier line setting this quarter, Abecma generated
Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to
Approximately
Ended quarter with approximately
Conference call today at 8:00 AM ET
“This year has been transformative for 2seventy, and we enter the second half in a strong financial and operational position, poised for commercial growth,” said Chip Baird, CEO. “We dramatically reduced our cost structure and strengthened our balance sheet with the completion of the sale of our oncology R&D business to Regeneron and the sale of our Hemophilia A program and gene editing technology to Novo Nordisk. These changes move us closer to achieving quarterly profitability by the end of 2025. We were pleased to see that Abecma turned a corner in the second quarter, recording modest growth in revenue in the
ABECMA COMMERCIAL AND REGULATORY HIGHLIGHTS
-
Second quarter Abecma® (idecabtagene vicleucel; ide-cel)
U.S. revenues, as reported by Bristol Myers Squibb (BMS), were$54 million - In order to restore growth for Abecma, 2seventy bio and BMS are focused on competitively differentiating Abecma’s safety and efficacy profile supported by the strength of the KarMMa-3 and real-world data, and anticipates continued growth in the second half of 2024.
-
2seventy bio and BMS share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the
U.S. The Company reported collaborative arrangement revenue of$4.4 million
SELECT SECOND QUARTER FINANCIAL RESULTS
-
Total revenues were
$9.0 million $36.0 million $21.4 million $77.7 million -
Research and development expenses were
$16.0 million $60.0 million $59.9 million $128.2 million -
Selling, general and administrative expenses were
$9.9 million $19.5 million $22.5 million $40.2 million -
Restructuring expenses were
$7.4 million $11.6 million -
The Company recognized a
$48.0 million $5.0 million -
Net income was
$24.9 million $42.1 million $27.8 million $89.1 million -
The Company has lowered its net cash spend range to
$40 -60 million -
Cash, cash equivalents, and marketable securities totaled
$201.9 million
Conference Call Information
2seventy bio will host a conference call and live webcast today, August 7 at 8:00 a.m. ET to discuss second quarter 2024 financial results and recent business highlights. Participants can access the conference call live via webcast which is available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call.
A replay of the webcast may be accessed from the “News and Events” page in the Investors and Media section of our website at https://ir.2seventybio.com/ and will be available for 30 days following the event.
ABECMA
ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
BOXED WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED CYTOPENIA and SECONDARY HEMATOLOGICAL MALIGNANCIES
- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ABECMA. Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
- Neurologic Toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ABECMA. Provide supportive care and/or corticosteroids as needed.
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. HLH/MAS can occur with CRS or neurologic toxicities.
- Prolonged Cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with ABECMA.
- T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA
- ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.
Warnings and Precautions:
Early Death: In KarMMa-3, a randomized (2:1), controlled trial, a higher proportion of patients experienced death within 9 months after randomization in the ABECMA arm (45/254;
Cytokine Release Syndrome (CRS): CRS, including fatal or life-threatening reactions, occurred following treatment with ABECMA. Among patients receiving ABECMA for relapsed refractory multiple myeloma in the KarMMa and KarMMa-3 studies (N=349), CRS occurred in
The most common manifestations of CRS (greater than or equal to
Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.
Of the 349 patients who received ABECMA in clinical trials, 226 (
Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of CRS and monitor patients for signs or symptoms of CRS for at least 4 weeks after ABECMA infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. Ensure that a minimum of 2 doses of tocilizumab are available prior to infusion of ABECMA. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.
Neurologic Toxicities: Neurologic toxicities, including immune-effector cell-associated neurotoxicity (ICANS), which may be severe or life- threatening, occurred concurrently with CRS, after CRS resolution, or in the absence of CRS following treatment with ABECMA.
In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, CAR T cell-associated neurotoxicity occurred in
At the safety update for KarMMa-3 study, one patient developed fatal neurotoxicity 43 days after ABECMA. In KarMMa, one patient had ongoing Grade 2 neurotoxicity at the time of death. Two patients had ongoing Grade 1 tremor at the time of data cutoff.
Cerebral edema has been associated with ABECMA in a patient in another study in multiple myeloma. Grade 3 myelitis and Grade 3 parkinsonism have occurred after treatment with ABECMA in another study in multiple myeloma.
Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of neurologic toxicities and monitor patients for signs or symptoms of neurologic toxicities for at least 4 weeks after ABECMA infusion and treat promptly. Rule out other causes of neurologic symptoms. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Counsel patients to seek immediate medical attention should signs or symptoms occur at any time.
Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in
In KarMMa-3, one patient had Grade 5, two patients had Grade 4 and two patients had Grade 3 HLH/MAS. The patient with Grade 5 HLH/MAS also had Grade 5 candida sepsis and Grade 5 CRS. In another patient who died due to stroke, the Grade 4 HLH/MAS had resolved prior to death. Two cases of Grade 3 and one case of Grade 4 HLH/MAS had resolved.
In KarMMa, one patient treated in the 300 x 106 CAR-positive T cells dose cohort developed fatal multi-organ HLH/MAS with CRS. In another patient with fatal bronchopulmonary aspergillosis, HLH/MAS was contributory to the fatal outcome. Three cases of Grade 2 HLH/MAS resolved.
HLH/MAS is a potentially life-threatening condition with a high mortality rate if not recognized early and treated. Treatment of HLH/MAS should be administered per institutional guidelines.
ABECMA REMS: Due to the risk of CRS and neurologic toxicities, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS. Further information is available at www.AbecmaREMS.com or contact Bristol-Myers Squibb at 1-866-340-7332.
Hypersensitivity Reactions: Allergic reactions may occur with the infusion of ABECMA. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA.
Infections: ABECMA should not be administered to patients with active infections or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after ABECMA infusion.
In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, infections (all grades) occurred in
Monitor patients for signs and symptoms of infection before and after ABECMA infusion and treat appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to standard institutional guidelines.
Febrile neutropenia was observed in
Viral Reactivation: Cytomegalovirus (CMV) infection resulting in pneumonia and death has occurred following ABECMA administration. Monitor and treat for CMV reactivation in accordance with clinical guidelines. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells. Perform screening for CMV, HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice.
Prolonged Cytopenias: In patients receiving ABECMA in the KarMMa and KarMMa-3 studies,
Monitor blood counts prior to and after ABECMA infusion. Manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines.
Hypogammaglobulinemia: In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, hypogammaglobulinemia was reported as an adverse event in
Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in
Monitor immunoglobulin levels after treatment with ABECMA and administer IVIG for IgG <400 mg/dl. Manage appropriately per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis.
Use of Live Vaccines: The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.
Secondary Malignancies: Patients treated with ABECMA may develop secondary malignancies. In KarMMa-3, myeloid neoplasms (four cases of myelodysplastic syndrome and one case of acute myeloid leukemia) occurred in
T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes.
Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1‑888‑805‑4555 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy.
Effects on Ability to Drive and Operate Machinery: Due to the potential for neurologic events, including altered mental status or seizures, patients receiving ABECMA are at risk for altered or decreased consciousness or coordination in the 8 weeks following ABECMA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.
Adverse Reactions: The most common nonlaboratory adverse reactions (incidence greater than or equal to
Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.
About Bristol Myers Squibb and 2seventy bio
Abecma is being jointly developed and commercialized in the
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day. For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
Cautionary Note Regarding Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of applicable laws and regulations. These statements include, but are not limited to: statements about our plans, strategies and expectations with respect to the commercial launch of ABECMA (ide-cel) in additional indications and in earlier line settings, including potential demand; statements regarding expected ABECMA
2seventy bio, Inc. |
||||||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||||||||||
(unaudited) |
||||||||||||||||
(in thousands) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
For the three months ended
|
|
For the six months ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
| Revenue: | ||||||||||||||||
| Service revenue | $ |
4,621 |
|
$ |
5,022 |
|
$ |
12,342 |
|
$ |
15,848 |
|
||||
| Collaborative arrangement revenue |
|
4,346 |
|
|
29,034 |
|
|
9,060 |
|
|
58,406 |
|
||||
| Royalty and other revenue |
|
- |
|
|
1,992 |
|
|
- |
|
|
3,415 |
|
||||
| Total revenues |
|
8,967 |
|
|
36,048 |
|
|
21,402 |
|
|
77,669 |
|
||||
| Operating expenses: | ||||||||||||||||
| Research and development |
|
16,013 |
|
|
59,980 |
|
|
59,944 |
|
|
128,226 |
|
||||
| Cost of manufacturing for commercial collaboration |
|
3,453 |
|
|
3,610 |
|
|
6,722 |
|
|
7,264 |
|
||||
| Selling, general and administrative |
|
9,857 |
|
|
19,489 |
|
|
22,516 |
|
|
40,209 |
|
||||
| Share of collaboration loss |
|
- |
|
|
- |
|
|
1,230 |
|
|
- |
|
||||
| Restructuring expenses |
|
7,398 |
|
|
- |
|
|
11,628 |
|
|
- |
|
||||
| Cost of royalty and other revenue |
|
- |
|
|
907 |
|
|
- |
|
|
1,548 |
|
||||
| Change in fair value of contingent consideration |
|
(685 |
) |
|
53 |
|
|
(2,415 |
) |
|
126 |
|
||||
| Total operating expenses |
|
36,036 |
|
|
84,039 |
|
|
99,625 |
|
|
177,373 |
|
||||
| Loss from operations |
|
(27,069 |
) |
|
(47,991 |
) |
|
(78,223 |
) |
|
(99,704 |
) |
||||
| Interest income, net |
|
2,527 |
|
|
3,090 |
|
|
5,388 |
|
|
5,139 |
|
||||
| Other income, net |
|
1,434 |
|
|
2,812 |
|
|
2,080 |
|
|
5,455 |
|
||||
| Gain on sale to Novo Nordisk |
|
47,987 |
|
|
- |
|
|
47,987 |
|
|
- |
|
||||
| Loss on assets held for sale to Regeneron |
|
- |
|
|
- |
|
|
(5,026 |
) |
|
- |
|
||||
| Income (loss) before income taxes |
|
24,879 |
|
|
(42,089 |
) |
|
(27,794 |
) |
|
(89,110 |
) |
||||
| Income tax (expense) benefit |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
||||
| Net income (loss) | $ |
24,879 |
|
$ |
(42,089 |
) |
$ |
(27,794 |
) |
$ |
(89,110 |
) |
||||
| Net income (loss) per share - basic | $ |
0.48 |
|
$ |
(0.83 |
) |
$ |
(0.53 |
) |
$ |
(1.89 |
) |
||||
| Net income (loss per share - diluted | $ |
0.45 |
|
$ |
(0.83 |
) |
$ |
(0.53 |
) |
$ |
(1.89 |
) |
||||
| Weighted-average number of common shares used in computing net income (loss) per share - basic |
|
52,186 |
|
|
50,966 |
|
|
52,129 |
|
|
47,238 |
|
||||
| Weighted-average number of common shares used in computing net income (loss) per share - diluted |
|
55,011 |
|
|
50,966 |
|
|
52,129 |
|
|
47,238 |
|
||||
2seventy bio, Inc. |
||||||
Condensed Consolidated Balance Sheet Data |
||||||
(unaudited) |
||||||
(in thousands) |
||||||
| As of June 30, 2024 |
As of December 31, 2023 |
|||||
| Cash, cash equivalents and marketable securities | $ |
201,873 |
$ |
221,805 |
||
| Total assets |
|
517,896 |
|
565,426 |
||
| Total liabilities |
|
283,092 |
|
310,126 |
||
| Total stockholders' equity |
|
234,804 |
|
255,300 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807192042/en/
Investors and Media:
Vicki Eatwell, CFO
vicki.eatwell@2seventybio.com
Kelli Koenig
kkoenig@realchemistry.com
Source: 2seventy bio, Inc.
FAQ
What revenue did Abecma generate in the second quarter of 2024?
What was 2seventy bio’s net income for Q2 2024?
What were 2seventy bio’s total revenues for Q2 2024?
How has 2seventy bio reduced its operating expenses?
What is 2seventy bio’s cash runway as of Q2 2024?
